
FDA Clears Pulse Biosciences to Begin nsPFA AFib Trial
Pulse Biosciences Secures FDA IDE Approval to Launch nsPFA Cardiac Surgery Study for Atrial Fibrillation Treatment Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company pioneering nonthermal ablation therapies through its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) platform, has reached…












